Prostate cancer and PARP inhibitors: progress and challenges

Related Experiment Video

Updated: Nov 11, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.8K

Diego Teyssonneau1, Henri Margot2, Mathilde Cabart3

  • 1Department of Medical Oncology, Institut Bergonie, Bordeaux, France. d.teyssonneau@bordeaux.unicancer.fr.

Journal of Hematology & Oncology
|March 30, 2021
PubMed

Insights

PARP inhibitors offer new hope for metastatic castration-resistant prostate cancer (mCRPC) by targeting DNA repair defects. Olaparib shows survival benefits, but challenges remain for broader PARP inhibitor use.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains a lethal disease despite recent survival improvements.
  • Alterations in DNA-damage response (DDR) genes are prevalent in advanced prostate cancers, indicating a potential therapeutic vulnerability.

Purpose of the Study:

  • To review the rationale, development, and clinical application of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in prostate cancer.
  • To discuss biomarker strategies and future challenges associated with PARP inhibitor therapy in mCRPC.

Main Methods:

  • Literature review synthesizing data on PARP inhibitors in prostate cancer.
  • Analysis of biomarker-based approaches and clinical trial outcomes.
  • Discussion of current challenges and future directions for PARP inhibitor therapy.

Main Results:

  • PARP inhibitors, such as olaparib, have demonstrated overall survival benefits in mCRPC patients with homologous recombination repair (HRR) deficiencies.
  • The development of PARP inhibitors is supported by the synthetic lethality principle in tumors with DDR gene alterations.
  • Biomarker-driven approaches are crucial for identifying patients likely to respond to PARP inhibitors.

Conclusions:

  • PARP inhibitors represent a significant advancement in treating mCRPC, particularly for patients with specific genetic alterations.
  • Further research and optimized clinical strategies are needed to overcome existing challenges and expand the use of PARP inhibitors.
  • Personalized medicine approaches, guided by biomarkers, are essential for maximizing the efficacy of PARP inhibitors in prostate cancer treatment.
Keywords:
DNA repairHomologous recombination repairPARP inhibitorsProstate cancers

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

922
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
311
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K